Inhibition of murine ige and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide

Clinical and Experimental Immunology

Volumn 115, Issue 2, 1999, Pages 221-228

  Jarman, E R ^a   Kuba, A ^a   Montermann, E ^a   Bartlett, R R ^a,b   Reske Kunz, A B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SANOFI   (France)

Author keywords

Immediate cutaneous hypersensitivity responses; Leflunomide; Ovalbumin; Serum IgE

Indexed keywords

IMMUNOGLOBULIN E; LEFLUNOMIDE; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL TRANSFER; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HELPER CELL; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; SKIN ALLERGY;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ALLERGENS; ANIMALS; ANTIBODY FORMATION; DOWN-REGULATION; FEMALE; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOLOGIC MEMORY; INTERLEUKIN-5; ISOXAZOLES; MICE; MICE, INBRED BALB C; OVALBUMIN; SKIN DISEASES; T-LYMPHOCYTES; VACCINATION;

EID: 0032895514     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00777.x     Document Type: Article

References (32)

1. 1 Popovic S, Bartlett RR. The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 1987; 21:284-6.
2. 2 Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 1994; 42:167-72.
3. 3 Glant TT, Mikecz K, Brennan F, Negroi G, Bartlett RR. Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions 1994; 41:C266-70.
4. 4 Schorlemmer HU, Bartlett RR. Therapeutic activity of leflunomide in acute and chronic relapsing experimental allergic encephalomyelitis. Agents Actions 1994; 41:C271-3.
5. 5 Bartlett RR, Dimitrijevic M, Matter M et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32:10-21.
6. 6 Bartlett RR, Mattar T, Weithmann U, Anagnostopoulos H, Popovic S, Schleyerbach R. Leflunomide (HWA 486): a novel immunorestoring drug. In: Therapeutic approaches to inflammatory diseases. Amsterdam: Elsevier North-Holland 1989:215-28.
7. 7 Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. In: Arthritis and rheumatism. Lippincott-Raven Publishers, 1995; 38:1595-603.
8. 8 Stenius B, Wide L, Seymour WH, Holford-Strevens V, Pepys J. Clinical significance of specific IgE to common allergens. Relationship of specific IgE against Dermatophagoides spp. and grass pollen to skin and nasal tests and history. Clin Allergy 1971; 1:37-55.
9. 9 Ishizaka K. Regulation of IgE synthesis. Annu Rev Immunol 1984; 2:159-82.
10. 10 O'Hehir RE, Garman RD, Greenstein JL, Lamb JR. The specificity and regulation of T-cell responsiveness to allergens. Annu Rev Immunol 1991; 9:67-95.
11. 11 Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991; 88:935-42.
12. 12 Kay AB, Ying S, Varney V et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony stimulating factor, in allergen-induced late phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173:775-8.
13. 13 Broide DH, Gleich GJ, Cuomo AJ et al. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991; 88:637-48.
14. 14 Baniyash M, Eshhar Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 1984; 14:799-807.
15. 15 Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988; 18:97-104.
16. 16 Chong AS-F, Finnegan A, Jiang X et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55:1361-6.
17. 17 Siemasko KF, Chong AS-F, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61:635-42.
18. 18 Nikcevich DA, Finnegan A, Chong AS-F, Williams JW, Bremer EG. Inhibition of interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomide. Agents Actions 1994; 41:C279-82.
19. 19 Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483-510.
20. 20 Xu X, Williams JW, Gong H, Finnegan A, Chong AS. Two activities of the immunosuppressive metabolite of leflunomide, A77, 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996; 52:527-34.
21. 21 Chong AS, Rezai K, Gebel HM et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61:140-5.
22. 22 Williamson RA, Yea CM, Robson PA et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77, 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270:22467-72.
23. 23 Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, Chong AS-F. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-Ipr/Ipr mice. J Immunol 1997; 159:167-74.
24. 24 Brendel S, Zielinski T, Bartlett RR. Leflunomide induces transferable resistance to the auto-immune SLE-like disease of MRL/Ipr mice. Induction of self tolerance? Immunobiology 1995; 194:26 (Abstr.).
25. 25 Schorlemmer H-U, Seiler FR, Bartlett RR. Prolongation of allogenic transplanted skin grafts and induction of tolerance by leflunomide (HWA 486), a new immunosuppressive isoxazol derivative. Transplant Proc 1993; 25:763-7.
26. 26 Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H. 'Infectious' transplantation tolerance. Science 1993; 259:974-7.
27. 27 Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994; 264:1587-9.
28. 28 Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270:12398-403.
29. 29 Takatsu K. Interleukin-5. Curr Opin Immunol 1992; 4:299-306.
30. 30 Purkerson JM, Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J Exp Med 1992; 175:973-82.
31. 31 Oettgen HC, Martin TR, Wynshaw-Boris A, Deng C, Drazen JM, Leder P. Active anaphylaxis in IgE-deficient mice. Nature 1994; 370:367-70.
32. 32 Hazenbos WL, Gessner JE, Hofhuis FM et al. Impaired IgG-dependent anaphylaxis and arthus reaction in FcγRIII (CD 16) deficient mice. Immunity 1996; 5:181-8.